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PENGEKSPRESIAN PENANDA TUMOR DAN PENENTUAN DENSITI 
SALURAN MIKRO DARAH PADA TUMOR PAYUDARA DIBAWAH 
ARUHAN MNU 
 
ABSTRAK 
Angiogenesis memainkan peranan penting dalam perkembangan tumor payudara. 
Perkaitan fenomena ini dengan pengekspresian penanda-penanda tumor payudara masih 
belum dihuraikan secara terperinci. Untuk kajian ini, pengaruhan tumor payudara 
dilakukan melalui suntikan karsinogen MNU (1-methyl-1-nitrosurea) pada tikus 
berumur 21 hari. Suntikan dilakukan secara intraperitoneal pada dos 70 mg/kg berat 
badan selama 3 hari berterusan. Tumour yang terhasil kemudiannya diinterven dengan 
faktor angiogenesis; bFGF dan PF4 pada dos 10µg/tumor. Saiz tumbesaran tumor 
dipantau. Pengekspresian gen penanda seperti ER, PR, EGFR, cerbB2, E-cadherin dan 
LR pada sampel tumor telah dikaji berdasarkan analisis  immunohistokimia dan 
RTPCR. Aktiviti angiogenesis pula telah dikaji berdasarkan perkiraan densiti saluran 
darah mikro, hasil daripada penandaan FVIII-RA secara teknik immunohistokimia. 
Keputusan histologi menunjukkan kebanyakan tumour payudara aruhan MNU adalah 
malignan yang terdiri daripada jenis cribriform berbanding jenis papilari. Kebanyakan 
ketumbuhan jenis benin dan pre-neoplastik aadalah pada tumour saiz kurang daripada 
1.2cm. Tumor di bawah aruhan angiogenesis mempunyai jenis histologi yang sama 
dengan kontrol. Penyekatan angiogenesis menunjukkan peningkatan tumor nekrosis dan 
bilngan tumor jenis ’NST’. Tumbesaran tumor pada kontrol menunjukkan 
kebergantungan terhadap salur darah peritumoral dan intratumoral. Peningkatan 
bilangan salur darah di intratumoral adalah lebih signifikan daripada di peritumoral. 
Tumour payudara yang dirawat oleh PF4 mempunyai penurunan salur darah yang 
significant manakala tumour payudara yang dirawat oleh bFGF tidak menunjukkan 
sebarang peningkatan salur darah yang signifikan. Semakin tumor membesar, terdapat 
 xx
peningkatan ekspresi ER, PR, EGFR dan cerbB2. Pengekspresian EGFR dan cerbB2 
berterusan meningkat walaupun pada keadaan dibawah aruhan ataupun penyekatan 
angiogenesis. Kami juga mendapati peningkatan tumour invasif pada kumpulan PF4 
disebabkan oleh penurunan ekspresi ER dan PR, dan peningkatan LR. Kami juga 
menjumpai perkaitan yang signifikan di antara peningkatan MVD dengan 
pengekspresian berlebihan ER, PR, EGFR, cerbB2 dan LR mRNA, dan penurunan E-
cadherin mRNA pada kontrol. Perkaitan ini dilihat berlaku samada di kawasan 
peritumoral mahupun intratumoral.  Terdapat juga perkaitan yang signifikan di antara 
peritumoral MVD dengan ekspresi ER, PR dan LR pada kumpulan bFGF. Perkaitan 
yang signifikan turut dikesan di antara intratumoral MVD dengan ekspresi ER dan PR 
pada  kumpulan PF4. Penutupnya, penemuan kami menunjukkan penurunan bekalan 
darah kepada tumor payudara menyebabkan peningkatan keagresifan tumor yang 
berdasarkan kehadiran fenotip agresif pada kumpulan PF4 dengan penurunan ER dan 
PR di kawasan intratumoral. Walaupun fenotip tumor pada kumpulan di bawah aruhan 
angiogenesis adalah sama dengan control, kadar pertumbuhan tumor yang cepat pada 
kumpulan ini di sokong oleh perkaitan yang signifikan dengan peningkatan ekspresi 
ER, PR dan LR pada kawasan peritumoral. Kami juga mendapati ekspresi EGFR dan 
cerbB2 dalam mempengaruhi tumbesaran tumor dan penurunan E-cadherin tidak 
menunjukkan kebergantungan terhadap angiogenesis. 
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EXPRESSION OF TUMOUR MARKERS AND DETERMINATION OF 
MICROVESSEL DENSITY IN MNU-INDUCED BREAST TUMOUR  
 
ABSTRACT 
Angiogenesis plays an important role in breast tumour development. The association 
of this phenomenon with the expression of breast tumour markers has not been fully 
elucidated. In this study, breast tumours were induced by injecting rats intraperitoneally 
with 1-methyl-1-nitrosurea (MNU) at dose of 70 mg/kg body weight in 3 consecutive 
days into 21-days old rats. The breast tumours were then subjected to intratumoural 
angiogenesis promotion using basic Fibroblast Growth Factor (bFGF) or inhibition 
using Platelet Factor 4 (PF4) at dose 10µg/tumour. The size of the tumours was 
monitored. The tumour tissues taken were subjected to quantitative-RTPCR for ER, PR, 
EGFR, cerbB2, E-cadherin and LR expression. Angiogenesis was determined by 
microvessel density with immunohistochemical staining for FVIII-RA. Histological 
findings showed most of the MNU-induced breast tumours were malignant where 
cribriform type predominated papillary type. Benign and preneoplastic lesions were 
seen mainly in tumours of size less than 1.2 cm. Promoting angiogenesis appear to have 
similar histological features with the control group. We noted that suppression of 
angiogenesis appeared to increase tumour necrosis and the number of diffuse infiltrating 
ductal carcinoma, not specified type (NST). It was clearly seen that tumour growth in 
control group shows dependency on peritumoural and intratumoural blood vessels. 
There was significant increase in the number of intratumoural blood vessels compared 
to peritumoural blood vessels. PF4-treated breast tumours have significant reduction of 
tumour blood vessels and bFGF-treated breast tumours do not show any significant 
increase of tumour blood vessel. As tumour grew, there was significant increase of ER, 
PR, EGFR and cerbB2 expressions. The expressions of EGFR and cerbB2 continue to 
 xxii
increase irrespective of whether angiogenesis is increased or suppressed. We also noted 
that the invasiveness of breast tumours was increased in PF4-treated group by decrease 
expressions of ER and PR; and increase expression of LR. We found a significant 
association between increased MVD and overexpressions of ER, PR, EGFR, c-erbB2 
and LR mRNA, and downregulation of E-cadherin mRNA expression in the control 
group. This association occurs irrespective whether the MVD is in peritumoural or 
intratumoural regions. There was also significant association between peritumoural 
MVD with the expressions of ER, PR and LR seen in bFGF-treated group. There was 
significant association between intratumoural MVD with the expressions of ER and PR 
seen in PF4-treated group. In conclusion, our findings have shown that reduction of 
blood supply to breast tumour causes increase aggressiveness of the tumour as 
illustrated by the presence of more aggressive phenotypes in the PF4-treated group with 
down regulations of ER and PR in the intratumoural region. Eventhough tumour 
phenotype in the angiogenic promoted group was similar to the control group, the 
growth rate was faster and this was supported by significant association with increased 
expressions of ER, PR and LR in the peritumoural region. We also noted that 
expressions of EGFR and cerbB2 in promoting tumour growth and down regulation of 
E-cadherin were independent of angiogenesis.  
 
 
CHAPTER ONE 
INTRODUCTION 
1.1 Introduction 
 
In the present world, breast cancer is the most common threats, and 
predominantly being diagnosed among women. Sasco indicated that about 1, 050, 000 
cases of breast cancer are reported worldwide in year 2000 with mortality cases of 
372,000 (Sasco, 2003). The number is increasing year by year. 
 
It has been noted that the developed countries had the highest rate of breast cancer 
incidence in contrast to developing countries (Parkin et al., 2005, Lacey et al., 2002, 
Parkin et al., 2001). United States is estimated to have approximately 212,920 of new 
breast cancer cases with 40,970 deaths among women in 2006 (Smigal et al., 2006). In 
European countries, the breast cancer is even higher with an estimate of 370, 100 new 
cases and 129 900 deaths were diagnosed in year 2004 (Boyle and Ferlay, 2005 a). 
However, the breast cancer rate is also seen to increase in the Asia countries that 
commonly have low incidence of breast cancer. The same phenomenon is also noted in 
Malaysia. Data from the National Cancer Registry of Malaysia for 2004 showed an age-
standardised incidence rate (ASR) of 46.2 per 100,000 women (Yip et al., 2006) 
.  
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Figure 1.1. Age standardized (world) incidence and mortality rates, female breast cancer 
in selected countries, 2002 estimates (Parkin et al., 2005). 
 
Delay in seeking diagnosis among women with breast cancer has been found to be 
the major factor for the difficulty in providing better treatment to the patient. Many of 
them had advance breast cancer by the time diagnosis was made. Distant metastasis 
progression of the breast cancer is commonly associated with the increasing cases of 
morbidity and mortality cases in women.  
 
Many great efforts have been done in order to improve the early detection of 
breast cancer as well as treatment strategies directed towards this malignancy.  More 
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attention needs to be given to the investigation on biological progressions of the breast 
cancer. Controlling the mechanisms of tumour growth at the beginning of the process is 
important apart from treating the solid tumour itself. There are many strategic pathways 
that can be manipulated including initial and sustain of tumour growth, loss of cell-cell 
adhesions, increase cell-stromal interaction and further growth with the final event of 
angiogenesis.  
 
Angiogenesis is a growth process of new blood vessels from existing vasculature, 
which enable tumour cells to increase their blood supply. This process is an important 
step for tumour growth, progression and metastasis (Pandya et al., 2006, Sledge, 2000). 
Realizing this has encouraged researchers to pursue further to investigate on how tumours 
send out signals to recruit new blood vessels. This hopefully will help us in controlling 
and probably eradicate the ability of the tumour in manipulating the angiogenic switch. 
Angiogenic processes in breast tumour samples can be assessed by measuring the 
molecules involved in the establishment of the tumour vasculature, including angiogenic 
growth factors and their receptors, cell adhesion molecules, proteases and markers of 
activated, proliferating, cytokine stimulated or angiogenic vessels.  
 
Previous studies describe the association between angiogenesis and tumour 
metastases and prognosis (Gasparini and Harris, 1995, Gasparini et al., 1995, Bosari et 
al., 1992, Weidner et al., 1991, Liotta et al., 1991). Figure 1.2 shows a diagram of this 
association which was illustrated by Folkman, 1995. However, very few studies have 
been done, especially at experimental level to look at the role of angiogenesis at the early 
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phase of tumour development. It is important to investigate to see whether angiogenesis 
is dependent or not on the early events of breast tumour development.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. The development of heterogeneity in the angiogenic phenotypes in a primary 
tumour and its relation to metastasis potential (Folkman, 1995). 
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The mechanism of breast tumourigenesis entails multiple events that are mediated 
under several cellular interactions between cancer cells, growth factors and components 
of extracellular matrix. In the current study, Estrogen Receptor (ER), Progesterone 
Receptor (PR), Epidermal Growth Factor Receptor (EGFR), cerbB2, E-cadherin and 
Laminin Receptor (LR) are the selected markers to observe such interactions in breast 
tumourigenesis. 
 
Early event in tumourigenesis such as dysregulated/ autoregulated proliferation 
involves over expression of ovarian hormone receptors i.e. ER and PR (Russo and Russo, 
2006). Further growth of tumour cells is aided by regulation of growth factor receptors 
such as EGFR and cerbB2. The overexpression of both receptors has been identified in 
primary breast tumour and is shown to be maintained throughout tumour progression 
(Tsutsui et al., 2003). E-cadherin is shown to be the principle adhesion molecule that 
promotes dedifferentiation of breast cancer cells (Heinmann et al., 2000). Decrease levels 
of E-cadherin causes the loss of cell-cell attachment in breast cancer. Other important 
breast tumourigenesis event is the cell to stromal interaction. The event has been shown 
to be regulated by the overexpression of LR in breast cancer (Givant-Horwitz et al., 
2005). 
 
Being able to understand the interactions between the above receptors’ expressions 
associated with angiogenic activity may help us to design further the study on how to 
stop certain important tumour signals or to prevent the tumour from getting more 
aggressive or to destroy it completely.  
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 Human breast development  
The breast is the most frequently diagnosed malignancy in the female population 
(Boyle and Ferlay, 2005 b). Changes in human breast associated with infantile growth, 
puberty, pregnancy, lactation and post-menopausal regression have been studied (Russo 
and Russo, 2004). Further study need to be carried out to understand how human breast 
development is influenced by those endocrinological and reproductive events. This will 
help to identify the risks of developing breast cancer. 
 
2.1.1 Mammary gland morphogenesis 
Normal breast tissue is comprised of epithelial and stromal elements. The 
epithelial part consists of branching ducts which connect to the lobules and to the nipples 
(Figure 2.1). The stroma part is composed of connective tissues that are surrounded by 
fat. In normal breast structure, the stroma makes up the majority of the breast volume.  
 
Human mammary gland morphogenesis occurs in a lifelong process from 
embryonic life to senescence. The process can be divided into two different stages; the 
developmental stage and the differentiation stage. The developmental stage involves 
initial steps of mammary gland transformation which include the progressive processes of 
ductal elongation, branching and sprouting of ductules, and formation of lobules structure 
(Russo et al., 2005). Lobules are the structural and functional milk-producing units of the 
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breast. Russo et al. (1992) termed the lobule unit as terminal ductal lobular unit (TDLU).  
An average of 4-11 ductules that cluster around a terminal duct is said to form TDLU. 
Cell proliferation and differentiation occur almost simultaneously in the formation of 
lobules.  
 
The changes in lobule transition are most marked during the time of puberty 
(Russo et al., 2005, Russo et al., 2002). Less differentiated structures of terminal ducts 
and lobules type 1(Lob 1) are found in the breasts of young women. Progressions of 
lobules type 2(Lob2) is also seen. Only minimal formation of lobules type 3(Lob 3) is 
observed.  In contrast to young women, adult women have completed the cycle of lobular 
development with the formation of lobules type 4 (Lob4). This occurs particularly during 
pregnancy and lactation. The presence of Lob4 indicates maximum expression of 
development and differentiation of the adult glands.  
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Figure 2.1. Anatomy of the human breast, a lobe and a TDLU. (Tabár et al., 1996) 
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2.1.2 Epithelial cell types of the breast 
Histologically, the ductal and lobular structures are lined by continuous layer of 
luminal epithelial cells (ECs). The luminal epithelial in turn is surrounded by a basal, 
layer composed of myoepithelial cell and the basement membrane. Similar type of 
luminal epithelial is seen in both human and animal model (Thompson et al., 2000). 
Differences between the myo- and luminal phenotype have been described based on the 
type of protein expression (Russo and Russo, 2004). It has been noted that the luminal 
cells express cytokeratins and nuclear receptors for ovarian hormone receptors more 
prominently compared to myoepithelial cells. In young rats, more than 90% of the 
steroid-induced epithelial cell proliferation occurs in the luminal cells (Perusinghe et al., 
1992). 
 
2.1.3 Hormonal influences on the development of the breast  
In both human and animal experimental studies, it is well-established that the 
breast is a hormone-responsive organ. The mechanism of breast development occurs in a 
synchronous manner involving specific hormonal and growth factor stimuli. The 
responses to hormonal influences are to regulate cell proliferation, cell differentiation and 
apoptosis.  
 
Estrogen hormone plays a major role in promoting human breast development. 
The initial report on the estrogen influences has been carried out by Beatson et al. in 
1869 (Russo and Russo, 2004). They have shown that removal of ovaries is known to 
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induce the risk for developing breast cancer. The findings promote further studies on 
using anti-estrogen agents to suppress breast tumour. 
 
It has been shown in animal studies that estrogen stimulation through estrogen 
receptor-α (ER-α) induce elongation and branching of the ducts. The activities reach a 
maximum limit at prepubertal age for rats. Gene-knockout studies have demonstrated that 
mammary glands fail to develop beyond the prepubertal stage in mice lacking ER-α 
(Korach et al., 1996). The estrogen receptor-β (ER-β) is also required for normal lobule-
alveolar development as suggested by the discovery of larger alveoli and less epithelial 
component in ER-β -/- mice compared to wild type controls (Foster et al., 1991).  
 
Progesterone and prolactin activities during the onset of sexual maturity increase 
the branching and size of alveolar buds. The activities occur in every estrous cycle until 
the rat reaches the age of 63 days. During pregnancy, progesterone has been shown to 
contribute to ductal branching and lobule-alveolar development that promote milk 
production (Conneely et al., 2003, Conneely and Lydon, 2000). Prolactin also acts 
directly on the mammary epithelium to induce lobule-alveolar development in pregnant 
animals (Brisken et al., 1999). A prolactin receptor-knockout mouse model revealed that 
a functional prolactin receptor (PRLR) is required for mammary gland development and 
milk production during pregnancy (Kelly et al., 2002).  
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2.2 Breast tumour  
2.2.1 The site origin of breast tumour 
Studies have shown that TDLU is the most naturally target site of malignancy in 
human breast (Russo et al., 2005, Russo et al, 1992). The structure has been shown to 
have the highest proliferation index, concentration of estrogen receptors and number of 
blood vessels per lobular structure (Russo and Russo, 2004). The peak proliferation 
activities of TDLU are commonly associated with human development in the early 
adulthood. This supports the fact that the breast is more susceptible to carcinogen and 
prone to undergo neoplastic transformation at the early maturity phase. 
 
In rats, the terminal end bud (TEB) is considered the structure comparable to 
TDLU. It has been found that the highest proliferation activity and rate of carcinogen 
binding to the DNA of TEBs are in pre-pubertal rats (Russo et al., 1992). In addition, 
higher incidence of breast cancer is usually seen when rats are exposed to carcinogens at 
a young age. Thus, this may supports that the susceptibility on breast to be cancerous 
occurs at the early age of human development.  
 
2.2.2 Breast tumour pathogenesis 
The important feature of breast malignancy is the loss of tubular-alveolar pattern 
of the mammary gland. This pattern is usually maintained in benign tumours i.e. the 
adenomas and fibroadenomas. The characteristics of benign lesions in human and rat 
have been previously described (Thompson et al., 2000). A wide spectrum of benign 
lesions has been observed in human while a very limited number of benign lesions are 
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seen in rats. The subtypes of benign lesions in rat model include fibroadenoma, 
mammary gland adenoma, papillary cyst adenoma, intraductal papilloma and epidermal 
inclusion cyst.  
The histopathology characteristics that are used to sub-classify breast cancer into 
its categories depend on where in the glandular or ductal unit of the breast the cancer 
arises. Ductal carcinomas begin in the ducts, while lobular carcinomas have a pattern 
involving the lobules or glands. It is well understood that all invasive ductal and invasive 
lobular carcinomas originate either in the terminal duct or the lobule. From Russo et al. 
(2005), it is noticed that both invasive ductal and invasive lobular carcinomas originate 
from the intralobular ducts of the TDLU.  
Cancer cells that remain confined to the lobule and the ducts are called 'in situ' or 
'non-invasive'. They are usually referred to as pre-malignant lesions. This is due to the 
fact that cancer cells have not yet gained the ability to spread to other parts of the body.  
The types of premalignant lesions have been identified in human as well in animal 
models (Thompson and Singh, 2000, Thompson et al., 2000). Higher occurrences of 
premalignant of breast lesions are found in animal model. The subtypes were cribriform 
and papillary DCIS (ductal carcinoma in situ) and hyperplasia of the epithelium which is 
also known by the term Intraductal Proliferation (IDP). The high incidence of pre-
malignant lesions encourages researchers to use rat model in studying the mechanisms of 
breast tumourigenesis in early stages of development.  
The premalignant lesions are precursors of invasive ductal or lobular breast 
tumours. The occurrence of premalignancy lesions is associated with the risk of 
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developing breast cancer (Page et al., 2000). The increasing relative risk (RR) of breast 
cancer associated with such premalignant lesions has been found to correlate the 
increased proliferation and accumulation of genetic damage (Allred et al., 2001, Allred 
and Mohsin, 2000). However, there are also tumours that arise from a site with no 
observed precursor lesion. Anderson and Miller supported this by reporting that invasive 
tumours are not always associated with local DCIS or LCIS (Anderson and Miller, 1994). 
An invasive cancer is one in which the cells have moved outside the ducts and 
lobules into the surrounding breast tissue. This type of cancer is seen mostly in humans 
and has been classified into the 'special' and 'no special' type (NST). Invasive carcinoma 
of NST is the commonest type of breast cancer in human which accounts for up to 85% 
of cases. Similar findings were also observed in rats that exhibited high frequency of 
NST adenocarcinomas (Thompson et al., 2000). Special types of carcinomas that have 
been observed in human are invasive lobular carcinoma, invasive tubular, cribriform, 
medullary and mucinous cancers. Many of the special type cancers have better prognosis, 
which in other words, gave a higher chance of survival among patients compared to the 
NST type. Majority of the invasive carcinoma subtypes that have been observed in rat 
model were cribriform, papillary and NST (Thompson et al., 2000, Thompson et al., 
1995). Other subtypes of human breast carcinomas were uncommonly observed in rats. 
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2.3 Angiogenesis  
2.3.1 Biological background 
2.3.1.1 Mechanism of angiogenesis 
Angiogenesis is a process of new blood vessel formation from existing 
vasculature (Folkman, 2003, Kerbel, 2000, Fokman, 1995). This phenomenon plays an 
important role in a variety of physiological and pathological processes. In physiological 
conditions, angiogenesis occurs in embryo development, wound healing and response to 
ovulation. 
 
All tissues develop a vascular network that provide cells with nutrients and 
oxygen and enable them to eliminate metabolic wastes. This process is inert in normal 
tissues and becomes active in rapidly growing tissues.  Angiogenesis requires cooperation 
and interaction between a variety of cells, growth factors, and components of the 
extracellular matrix. The angiogenic process is summarized as follows: 
1 A cell that is activated by lack of oxygen releases angiogenic molecules. This 
event promotes the proliferation of inflammatory and endothelial cells.  
2 During migration, inflammatory cells also secrete molecules that intensify the 
angiogenic stimuli. 
3 Endothelial cells play a major role the formation of blood vessels. The cells 
responded to the angiogenic call by differentiating and secreting matrix 
metalloproteases (MMP). The MMPs digest the blood-vessel walls and enable 
them to escape and migrate towards the site of the angiogenic stimuli. 
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4 The digestion of blood vessel walls supports the proliferative and migratory 
activity of endothelial cells. Subsequently, the endothelial cells form a capillary 
tube by altering the arrangement of their adherence-membrane proteins. 
5 Finally, the capillaries emanating from the arterioles and venules joined together. 
This process is defined as anastomosis which results in a continuous blood flow. 
Angiogenesis exerts its normal physiological activity through a series of ‘on’ and 
‘off’ regulatory switches (Pandya et al., 2006). This angiogenic switches are maintained 
through a fine balance of angiogenesis modulators that induce the formation of blood 
vessels (the ‘on’ switches) and those that inhibit the process (the ‘off’ switches). When 
this balance is disturbed, it causes unrestrained blood-vessel formation in diseases that 
depends on angiogenesis. Downregulation of angiogenesis is seen in physiological 
diseases such as coronary artery disease (CAD), cardiac failure and tissue injury. Up 
regulation angiogenesis in turn is seen in some pathological conditions such as 
arthrosclerosis, diabetic retinopathy and cancer.  
 
2.3.1.2 Measurement of blood vessel 
Microvessel measurement is clinically important in cancer studies as well as in 
other angiogenic-dependent diseases. Studies of various tumours revealed the significant 
correlation of microvessel density (MVD) with tumour growth and metastasis (Uzzan et 
al., 2004, Nisato et al., 2003).  MVD has been shown to be an important prognostic 
indicator in disease.  
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Recently, encourages researchers put their efforts to find ways to optimize the 
method measuring MVD. The most common counting technique that has been widely 
used is known as the ‘hot-spot’ technique (McGinley et al., 2002, Kerbel, 2000). The 
technique focuses on quantifying blood vessels as a reflection of angiogenesis in highly 
stained regions. The immunohistochemistry staining method is used for this purpose. A 
variety of blood vessel endothelium markers for the identification of microvessels in 
histological sections have been developed for routine purposes. The markers include 
Factor VIII-related antigen (FVIII-RA), CD31 or CD34 (Uzzan et al., 2004).  
 
FVIII-RA has been identified as the coagulation protein expressed by the 
endothelium of the blood vessels (Folkman, 1995). This marker has been widely used in 
immunohistochemical study for endothelial vascular’s staining. A study by Gasparini et 
al. (1995) has shown that high vessels count using FVIII-RA marker correlated well with 
the occurrence of nodal and distant metastases. Besides, microvessel counts stained by 
FVIII-RA are significantly related with stage II and stage III breast cancer (Bhatavdekar 
et al., 2000). Other endothelial markers i.e, CD31 and CD34 are also commonly 
described in previous studies but both markers show no association with breast cancer 
prognosis. Goulding et al. (1995) showed no correlation between positive CD31 staining 
with lymph nodes status, recurrence, distant metastases or overall survival. Paradiso et al. 
(2001) observed no correlation between positive CD34 with clinical or pathological 
features of the breast tumours 
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2.3.2 Modulation of angiogenic activity 
Angiogenesis is tightly controlled by a set of positive and negative modulators 
that are regulated in a fine balance condition. These molecules are produced by stromal 
and infiltrating tumour cells (Carmelliet and Jain, 2000). A study by Relf et al., (1997) 
noted that tumour cells express a variety of angiogenic modulators which relative 
production varies with time.  
 
Two important positive modulators that have been described are basic fibroblast 
growth factor (bFGF) and vascular endothelial growth factor (VEGF). The angiogenic 
activities of these molecules are found to be in synergistic manner. The angiogenic 
effects of these positive modulators are counterbalanced by inhibitory molecules such as 
angiostatin, endostatin, thrombospondin-1 (TSP-1), the 16-kD human prolactin fragment 
(16-kD human PRL), or platelet factor 4 (PF4). Table 2.1 shows multiple angiogenic 
factors and anti-angiogenic factors listed by Folkman, 1995. 
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Table 2.1 List of angiogenic factors and anti-angiogenic factors (Fokman, 1995). 
 
 
 
 
 
 
Endogenous angiogenic factors 
Endogenous negative regulators of 
endothelial-cell proliferation 
Basic Fibroblast Growth factors Platelet factor 4 
Acidic Fibroblast Growth factors Thrombospondin-1 
Transforming growth factor-alpha Tissue inhibitors of metalloproteinase 
(TIMP)-1 
Transforming growth factor-beta TIMP-2 
Vascular endothelial growth factor TIMP-3 
Platelet-derived endothelial cell growth 
factor 
Prolactin (16 kd fragment) 
Granulocyte colony-stimulating factor Angiostatin (38-kd fragment of 
plasminogen 
Placental growth factor bFGF soluble receptor 
Interleukin-8 Transforming growth factor-beta 
Hepatocyte growth factor Interferon Alfa 
Proliferin Placental proliferin-related protein 
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2.3.2.1 bFGF as the angiogenic promoter 
The most potent known angiogenic peptide is the bFGF (Folkman, 1995). This 
important pro-angiogenic factor has been found to be produced by tumour, stromal and 
endothelial cells. The factor stimulates endothelial proliferation, protease production, 
chemotaxis, and vascular tube formation (Gross et al., 1993).  
The role of bFGF in tumour angiogenesis has been extensively studied. It is suggested 
that triggering angiogenesis switch through upregulating pro-angiogenic gene and 
downregulating anti-angiogenic gene expression is one of the major mechanisms of 
bFGF-induced angiogenesis (Yue et al., 2006). Compagni et al. (2000) used the 
AdsFGFR (the recombinant adenovirus that expressing soluble fibroblast growth factor 
(FGF) receptor) to assess the FGF functions in tumour angiogenesis. They found that 
FGF receptors i.e. FGF-1 and FGF-2 exert highly pleiotropic functions during multiple 
stages of tumour development. Giavazzi et al., (2001) found that the expression of bFGF 
affects the initial growth and neovascularization of HEC-1-B human endometrial 
adenocarcinoma in nude mice. In addition, bFGF has been found to stimulate tumour 
vascularization in a synergistic action with VEGF although both growth factors are found 
to have separable role on vessel formation and tumour growth (Giavazzi et al., 2003) 
 
It is known that bFGF is a strong mitogen and chemotatic factor for vascular 
endothelial cells. During wound healing of normal tissues and in tumor development, the 
action of heparin sulfate proteoglycans (HSPGs) activates bFGF, thus mediating the 
formation of new blood vessels.  HSPGs modulate the binding of bFGF and VEGF to 
their respective receptors. A study by Javerzat et al. (2002) noted that the HSPGs 
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stabilize the bFGF/FGF receptor complex, protect bFGF from degradation and facilitate 
bFGF dimerization. They proposed that inhibitors may possibly disturb the bFGF activity 
in two ways; either by blocking the interaction of bFGF with its receptors or by 
disrupting the by-stander effect of HSPGs for efficient growth factor binding.  
 
It has been discovered that the anti-angiogenic factor acts directly against the 
action of bFGF. It is known that PF4 complexes with bFGF and inhibits heparin-induced 
bFGF dimerization (Perollet et al., 1998). Hegedorn et al. (2001) had characterized a 
peptide from C-terminus of PF4 which is thought to inhibit the angiogenic activity 
induced by bFGF. 
 
2.3.2.2 Platelet factor 4 (PF4) as the angiogenic inhibitor 
PF4 is an anti-angiogenic factor that inhibits angiogenesis and growth factor-
stimulated endothelial cell proliferation (Raouva et al., 2006). This blood coagulation 
factor is synthesized by megakaryocytes and seized normally in platelets. PF4 exerts the 
anti-angiogenic properties by binding to heparin and thereby neutralized the heparin 
activity. It is established that PF4/heparin complexes are highly immunogenic and obtain 
self-reacting anti-PF4/heparin antibodies in a T cell-dependent manner (Survana et al., 
2005). 
It has been noted that PF4 regulates angiogenesis in a negative manner by 
interfering bFGF and VEGF activity (Bikfalvi, 2004, Bikfalvi and Bicknell, 2002). The 
anti-angiogenic properties of PF4 were also described by Perrolet et al. (1998), where 
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they found that PF4 inhibited the bFGF-dimer formation or heparin-induced bFGF dimer 
formation.  
The PF4 displays an anti-angiogenic activity in vivo and inhibits tumour growth 
without affecting the proliferation rate of the cancerous cells (Yamaguchi et al., 2005). Li 
et al. (2003) found that viral vector-mediated cDNA transfer of PF4 resulted in inhibition 
of solid tumors through anti-angiogenic action in vivo. 
Based on those facts, it can be seen why PF4 is an important angiogenesis 
inhibitor in vitro and in vivo models. PF4 may also be developed into a therapeutic agent. 
One example is the study on C-terminal fragment of PF4. This peptide has been noted to 
inhibit angiogenic events induced by bFGF (Hegedorn et al., 2001).  
 
2.3.3 Tumour angiogenesis  
Angiogenesis performs a critical role in the development of cancer (Pandya et al., 
2006, Carmeliet and Jain, 2000). The development of new blood vessels is necessary both 
at the beginning and at the end of distant metastasis development. It has been found that 
solid tumors could potentially survive without stimulating angiogenesis. However, this 
activity is very limited to tumour size smaller than 1 to 2 cubic millimeters (Kerbel, 2000, 
Folkman, 1995). For further growth and spread, tumour cells need blood supply that will 
bring oxygen and nutrients and remove metabolic wastes. Oxygen and nutrients have 
difficulty diffusing into cells at the center of the tumor when the tumour has reached 
beyond the critical volume of 2 cubic millimeters. This causes a state of cellular hypoxia 
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that marks the onset of tumor angiogenesis. The latter mechanism describes the growth of 
blood supply from existing vessels were induced by the tumour itself. 
 
Albo et al. (2004) summarize four potential mechanisms by which tumours can 
stimulate angiogenesis:  
 
1 Tumours stimulate the sprouting of new blood vessels by secreting pro-
angiogenic factors (Folkman, 2003). Those pro-angiogenic factors are vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor, transforming 
growth factor beta and others.  
 
2 Tumour angiogenesis is stimulated by co-opting the existing vasculature. This is 
evidenced in Holash study, as they found that the angiogenic antagonist 
angiopoietin-2 and pro-angiogenic vascular endothelial growth factor (VEGF) 
play critical role of regulators of balance between vascular regression and growth 
(Holash et al., 1999). 
 
3 Angiogenesis is said to be contributed by circulating hematopoietic precursor 
cells from bone marrow (Lyden et al., 2001). The EC (endothelial cell) 
progenitors can supply the growth of blood vessels to ischemic areas and can 
deliver the anti- or pro-angiogenic agents to unrestrained angiogenesis sites. 
 
4 The fourth potential mechanism is ‘vascular-mimicry’ process. The process 
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involves the formation of vasculogenic-like networks by the tumour cells with 
simultaneous expression of vascular-associated cell markers (Sood et al., 2002). 
 
Understanding angiogenesis and its unique characteristics in tumour growth has 
provided insights into a number of ways to interrupt this process. Therapies targeting 
tumour angiogenesis are rapidly emerging and hold great promise. As a result, a number 
of anti-angiogenic agents are currently in pre-clinical and clinical studies. Thalidomide, 
endostatin, the anti-VEGF receptor SU5416 and recombinant humanized anti-VEGF 
monoclonal antibody are among the compounds for anti-angiogenic therapy (Gasparini et 
al., 2001, Eder et al., 2000, Mendel et al., 2000, Sledge, 2000). The therapy shows great 
potential when combine with chemotherapy and radiation therapy. 
 
2.3.3.1 Breast tumour angiogenesis   
The importance of angiogenesis in the growth of human breast cancer and their 
value as a marker of metastasis potential of tumour are well emphasized in previous study 
(Folkman, 2003). Weidner et al. (1991) demonstrated the significance correlation 
between tumour MVD in invasive breast cancer and the presence of axillary lymph nodes 
and distant metastases. This finding has also been confirmed by several experimental 
studies (Nisato et al., 2003, Gasparini and Harris, 1995, Gasparini et al., 1995, Weidner 
et al., 1992, Bosari et al., 1992, Liotta et al., 1991). Increased MVD is also associated 
with the transition from low grade to high grade in situ lesions (Engel et al., 1997). 
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It has been suggested that tumour MVD in breast cancer is an independent 
prognostic factor for disease free and overall survival. However, there appears to be 
arguments on assessing MVD in breast cancer patients due to the considerable variation 
in nodal status, duration of follow-up as well as the methods and criteria used for 
counting MVD (Gasparini et al., 1995, Simpson and Page, 1995).  
 
Previous studies have also shown the association between the tumour MVD and 
preinvasive lesions of the breast (Thompson et al., 2002, Vartanian and Weidner, 1995). 
The angiogenesis in in situ stage differs from that of invasive tumours. It was observed 
that there were increased blood vessels in the normal stroma around and beneath the in 
situ composition of tumour cells (Mc Ginley et al., 2002). This was in contrast to those 
seen in tumour cells of the invasive phase. The structure found in breast in situ tumours 
suggests that the angiogenic factors are strongly influenced the induction of tumour 
growth at the early steps. It is believed that those angiogenic factors are produced by the 
inflammatory and stromal cells rather than those produced from tumour cells themselves 
(Rosen, 2002, Linderholm et al., 2000). 
 
 
 
 
 
 
 
